Experimental Treatment of Ebola Virus Disease with Brincidofovir

Dunning, J; Kennedy, SB; Antierens, A; Whitehead, J; Ciglenecki, I; Carson, G; Kanapathipillai, R; Castle, L; Howell-Jones, R; Pardinaz-Solis, R; Grove, J; Scott, J; Lang, T; Olliaro, P; Horby, PW

dc.contributor.author	Dunning, J
dc.contributor.author	Kennedy, SB
dc.contributor.author	Antierens, A
dc.contributor.author	Whitehead, J
dc.contributor.author	Ciglenecki, I
dc.contributor.author	Carson, G
dc.contributor.author	Kanapathipillai, R
dc.contributor.author	Castle, L
dc.contributor.author	Howell-Jones, R
dc.contributor.author	Pardinaz-Solis, R
dc.contributor.author	Grove, J
dc.contributor.author	Scott, J
dc.contributor.author	Lang, T
dc.contributor.author	Olliaro, P
dc.contributor.author	Horby, PW
dc.date.accessioned	2016-09-15T15:09:39Z
dc.date.available	2016-09-15T15:09:39Z
dc.date.issued	2016-09-09
dc.date.submitted	2016-09-12
dc.identifier.citation	Experimental Treatment of Ebola Virus Disease with Brincidofovir., 11 (9):e0162199 PLoS ONE	en
dc.identifier.issn	1932-6203
dc.identifier.pmid	27611077
dc.identifier.doi	10.1371/journal.pone.0162199
dc.identifier.uri	http://hdl.handle.net/10144/618652
dc.description.abstract	The nucleotide analogue brincidofovir was developed to prevent and treat infections caused by double-stranded DNA viruses. Based on in vitro data suggesting an antiviral effect against Ebola virus, brincidofovir was included in the World Health Organisation list of agents that should be prioritised for clinical evaluation in patients with Ebola virus disease (EVD) during the West African epidemic.
dc.language	ENG
dc.language.iso	en	en
dc.publisher	Public Library of Science	en
dc.rights	Published by Public Library of Science, [url]http://www.plosone.org/[/url] Archived on this site by Open Access permission	en
dc.title	Experimental Treatment of Ebola Virus Disease with Brincidofovir	en
dc.identifier.journal	PloS One	en
refterms.dateFOA	2019-03-04T12:50:14Z
html.description.abstract	The nucleotide analogue brincidofovir was developed to prevent and treat infections caused by double-stranded DNA viruses. Based on in vitro data suggesting an antiviral effect against Ebola virus, brincidofovir was included in the World Health Organisation list of agents that should be prioritised for clinical evaluation in patients with Ebola virus disease (EVD) during the West African epidemic.